-
1.发明申请MODIFIED TWO-COMPONENT GELATION SYSTEMS, METHODS OF USE AND METHODS OF MANUFACTURE 审中-公开改性双组分凝胶系统，使用方法和制造方法公开(公告)号：US20140348800A1
公开(公告)日：2014-11-27
申请号：US14290752
申请日：2014-05-29
Applicant: Abbott Cardiovascular Systems Inc.
Inventor： Gene Michal , Shubhayu Basu
CPC classification number: A61K35/28 , A61K33/14 , A61K33/20 , A61K38/1858 , A61K38/363 , A61K38/4833 , A61L27/26 , A61L27/3873 , A61L27/52 , C12Y304/21005 , A61K2300/00 , A61K38/00
Abstract: A bioscaffolding can be formed from a mixture of gel components of different gelation systems. For example, a bioscaffolding can be formed by mixing at least two different components of at least two different two-component gelation systems to form a first mixture and by mixing at least two different components (other than the components that make up the first mixture) of the at least two different two-component gelation systems to form a second mixture. A treatment agent, such as a cell type or a growth factor, can be added to either the first mixture or the second mixture. In some embodiments, the treatment agent is not added to either mixture. The first mixture can be co-injected with the second mixture to form a bioscaffolding in an infarct region for treatment thereof.
Abstract translation: 生物支架可以由不同凝胶化系统的凝胶组分的混合物形成。 例如，生物支架可以通过混合至少两种不同的双组分凝胶化体系的至少两种不同组分形成第一混合物并通过混合至少两种不同组分（构成第一混合物的组分） 的至少两种不同的双组分凝胶化体系以形成第二混合物。 可以将第一混合物或第二混合物中的处理剂如细胞类型或生长因子加入。 在一些实施方案中，处理剂不加入任何混合物中。 可以将第一混合物与第二混合物共注射以在梗塞区域中形成生物支架，用于治疗它们。
-
公开(公告)号：US08828436B2
公开(公告)日：2014-09-09
申请号：US13888143
申请日：2013-05-06
Applicant: Abbott Cardiovascular Systems Inc.
Inventor： Syed Hossainy , Michael Ngo , Mikael Trollsas , John Stankus , Gene Michal
IPC: A61K35/28 , C07K17/08 , A61F2/00 , A61K47/48 , C08L89/00 , A61K47/42 , A61L27/38 , A61K9/00 , A61L27/52 , A61K47/34 , A61L27/48
CPC classification number: A61K47/42 , A61K9/0024 , A61K47/34 , A61L27/3804 , A61L27/3839 , A61L27/3895 , A61L27/48 , A61L27/52 , Y10S530/812 , Y10S530/815 , C08L89/00 , C08L71/02
Abstract: Compositions for forming a self-reinforcing composite biomatrix, methods of manufacture and use therefore are herein disclosed. Kits including delivery devices suitable for delivering the compositions are also disclosed. In some embodiments, the composition can include at least three components. In one embodiment, a first component can include a first functionalized polymer, a second component can include a second functionalized polymer and a third component can include silk protein or constituents thereof. In some embodiments, the composition can include at least one cell type and/or at least one growth factor. In some embodiments, the composition can include a biologic encapsulated, suspended, disposed within or loaded into a biodegradable carrier. In some embodiments, the composition(s) of the present invention can be delivered by a dual lumen injection device to a treatment area in situ, in vivo, as well as ex vivo applications.
Abstract translation: 本文公开了用于形成自增强复合生物基质的组合物，因此制造和使用方法。 还公开了包括适合递送组合物的递送装置的试剂盒。 在一些实施方案中，组合物可以包括至少三种组分。 在一个实施方案中，第一组分可以包括第一官能化聚合物，第二组分可以包括第二官能化聚合物，第三组分可以包括丝蛋白或其组分。 在一些实施方案中，组合物可以包括至少一种细胞类型和/或至少一种生长因子。 在一些实施方案中，组合物可以包括生物封装的，悬浮的，置于生物降解载体内或加载到可生物降解的载体中。 在一些实施方案中，本发明的组合物可以通过双腔注射装置原位，体内和离体应用递送至治疗区域。
-
公开(公告)号：US20130251764A1
公开(公告)日：2013-09-26
申请号：US13888143
申请日：2013-05-06
Applicant: Abbott Cardiovascular Systems Inc.
Inventor： Syed Hossainy , Michael Ngo , Mikael Trollsas , John Stankus , Gene Michal
CPC classification number: A61K47/42 , A61K9/0024 , A61K47/34 , A61L27/3804 , A61L27/3839 , A61L27/3895 , A61L27/48 , A61L27/52 , Y10S530/812 , Y10S530/815 , C08L89/00 , C08L71/02
Abstract: Compositions for forming a self-reinforcing composite biomatrix, methods of manufacture and use therefore are herein disclosed. Kits including delivery devices suitable for delivering the compositions are also disclosed. In some embodiments, the composition can include at least three components. In one embodiment, a first component can include a first functionalized polymer, a second component can include a second functionalized polymer and a third component can include silk protein or constituents thereof. In some embodiments, the composition can include at least one cell type and/or at least one growth factor. In some embodiments, the composition can include a biologic encapsulated, suspended, disposed within or loaded into a biodegradable carrier. In some embodiments, the composition(s) of the present invention can be delivered by a dual lumen injection device to a treatment area in situ, in vivo, as well as ex vivo applications.
Abstract translation: 本文公开了用于形成自增强复合生物基质的组合物，因此制造和使用方法。 还公开了包括适合递送组合物的递送装置的试剂盒。 在一些实施方案中，组合物可以包括至少三种组分。 在一个实施方案中，第一组分可以包括第一官能化聚合物，第二组分可以包括第二官能化聚合物，第三组分可以包括丝蛋白或其组分。 在一些实施方案中，组合物可以包括至少一种细胞类型和/或至少一种生长因子。 在一些实施方案中，组合物可以包括生物封装的，悬浮的，置于生物降解载体内或加载到可生物降解的载体中。 在一些实施方案中，本发明的组合物可以通过双腔注射装置原位，体内和离体应用递送至治疗区域。
-
公开(公告)号：US08697058B2
公开(公告)日：2014-04-15
申请号：US13623863
申请日：2012-09-20
Applicant: Abbott Cardiovascular Systems Inc.
Inventor： Shubhayu Basu , Gene Michal , Florian N. Ludwig , Jinping Wan , John Stankus
CPC classification number: A61L27/52 , A61L27/20 , A61L27/3604 , A61L27/3641 , A61L27/365 , A61L27/3804 , A61L27/3839 , C08L5/04
Abstract: The present invention relates to a method of making cytocompatible alginate gels and their use in the treatment of cardiomyopathy.
Abstract translation: 本发明涉及一种制备细胞相容性藻酸盐凝胶的方法及其在治疗心肌病中的应用。
-
-
-
Search Results
4
records
(took 0.018 seconds)
